Earnings ·
Repligen reports Q3 revenue of $209M, raises FY26 guidance to $844-$852M
RGENRepligen Corp
Repligen Corporation reported third-quarter revenue of $209.3 million, an 11% increase as reported and 12.5% organic growth compared to the prior year period. The company posted a GAAP loss per share of $0.68 due primarily to a $41.2 million intangible asset impairment charge, while adjusted earnings per share were $0.53. Repligen also raised its full-year 2026 revenue guidance to $844-$852 million, reflecting strong demand and the recent acquisition of BioLife Solutions. The company operates in the bioprocessing industry, developing technologies for biologics manufacturing.